T
Tong Zhang
Researcher at Princess Margaret Cancer Centre
Publications - 37
Citations - 2186
Tong Zhang is an academic researcher from Princess Margaret Cancer Centre. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 7, co-authored 21 publications receiving 2025 citations. Previous affiliations of Tong Zhang include University of Toronto & University Health Network.
Papers
More filters
Journal ArticleDOI
Erlotinib in lung cancer - molecular and clinical predictors of outcome.
Ming-Sound Tsao,Akira Sakurada,Jean-Claude Cutz,Jean-Claude Cutz,Chang-Qi Zhu,Chang-Qi Zhu,Suzanne Kamel-Reid,Suzanne Kamel-Reid,Jeremy A. Squire,Jeremy A. Squire,Ian A. J. Lorimer,Tong Zhang,Tong Zhang,Ni Liu,Ni Liu,Manijeh Daneshmand,Paula Marrano,Paula Marrano,Gilda da Cunha Santos,Gilda da Cunha Santos,Alain E. Lagarde,Frank C. Richardson,Lesley Seymour,Marlo Whitehead,Keyue Ding,Joseph L. Pater,Frances A. Shepherd,Frances A. Shepherd +27 more
TL;DR: Among patients with non-small-cell lung cancer who receive erlotinib, the presence of an EGFR mutation may increase responsiveness to the agent, but it is not indicative of a survival benefit.
Journal ArticleDOI
Circulating tumour DNA sequence analysis as an alternative to multiple myeloma bone marrow aspirates.
Olena Kis,Rayan Kaedbey,Signy Chow,Signy Chow,Arnavaz Danesh,Mark Dowar,Tiantian Li,Zhihua Li,Jessica Liu,Mark Mansour,Esther Masih-Khan,Tong Zhang,Scott V. Bratman,Scott V. Bratman,Amit M. Oza,Suzanne Kamel-Reid,Suzanne Kamel-Reid,Suzanne Trudel,Suzanne Trudel,Trevor J. Pugh,Trevor J. Pugh +20 more
TL;DR: A hybrid-capture-based Liquid Biopsy Sequencing (LB-Seq) method used to sequence all protein-coding exons of KRAS, NRAS, BRAF, EGFR and PIK3CA in 64 cfDNA specimens from 53 myeloma patients to >20,000 × median coverage is reported.
Journal ArticleDOI
A phase I study of the combination of ro4929097 and cediranib in patients with advanced solid tumours (PJC-004/NCI 8503)
Solmaz Sahebjam,Philippe L. Bedard,Vincent Castonguay,Z Chen,Michael Reedijk,Geoffrey Liu,Brenda Cohen,W-J Zhang,Blaise A. Clarke,Tong Zhang,Suzanne Kamel-Reid,Helen X. Chen,S. P. Ivy,Albiruni Ryan Abdul Razak,Amit M. Oza,E.X. Chen,Hal W. Hirte,A McGarrity,Lisa Wang,Lillian L. Siu,Sebastien J. Hotte +20 more
TL;DR: RO4929097 in combination with cediranib is generally well tolerated and preliminary evidence of antitumour efficacy with prolonged disease stabilisation in some patients with progressive malignancies warrants further clinical investigation.
Journal ArticleDOI
Comparison of Next-Generation Sequencing Panels and Platforms for Detection and Verification of Somatic Tumor Variants for Clinical Diagnostics
Maksym Misyura,Tong Zhang,Mahadeo A. Sukhai,Mariam Thomas,Swati Garg,Suzanne Kamel-Reid,Tracy Stockley,Tracy Stockley,Tracy Stockley +8 more
TL;DR: A combined workflow using both platforms enabled successful molecular profiling of 96% (621/644) of tumor samples, and provided an approach for verification of somatic variants not amenable to verification by Sanger sequencing (<15% variant allele frequency).
Journal ArticleDOI
Somatic Tumor Variant Filtration Strategies to Optimize Tumor-Only Molecular Profiling Using Targeted Next-Generation Sequencing Panels
Mahadeo A. Sukhai,Maksym Misyura,Mariam Thomas,Swati Garg,Tong Zhang,Natalie Stickle,Carl Virtanen,Philippe L. Bedard,Philippe L. Bedard,Lillian L. Siu,Lillian L. Siu,Tina Smets,Gert Thijs,Steven Van Vooren,Suzanne Kamel-Reid,Tracy Stockley,Tracy Stockley,Tracy Stockley +17 more
TL;DR: Overall the tumor-Only variant filtration strategy described in this study can define clinically relevant somatic variants from tumor-only analysis with sensitivity of 97% to 99% and specificity of 87% to 94%, and with significant potential utility for clinical laboratories implementing tumor- only molecular profiling.